167 related articles for article (PubMed ID: 31375625)
1. EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance.
Li S; Rodriguez J; Li W; Bullova P; Fell SM; Surova O; Westerlund I; Topcic D; Bergsland M; Stenman A; Muhr J; Nistér M; Holmberg J; Juhlin CC; Larsson C; von Kriegsheim A; Kaelin WG; Schlisio S
Proc Natl Acad Sci U S A; 2019 Aug; 116(34):16997-17006. PubMed ID: 31375625
[TBL] [Abstract][Full Text] [Related]
2. Deletion of the von Hippel-Lindau gene causes sympathoadrenal cell death and impairs chemoreceptor-mediated adaptation to hypoxia.
Macías D; Fernández-Agüera MC; Bonilla-Henao V; López-Barneo J
EMBO Mol Med; 2014 Dec; 6(12):1577-92. PubMed ID: 25385837
[TBL] [Abstract][Full Text] [Related]
3. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer.
Lee S; Nakamura E; Yang H; Wei W; Linggi MS; Sajan MP; Farese RV; Freeman RS; Carter BD; Kaelin WG; Schlisio S
Cancer Cell; 2005 Aug; 8(2):155-67. PubMed ID: 16098468
[TBL] [Abstract][Full Text] [Related]
4. RHOBTB3 promotes proteasomal degradation of HIFα through facilitating hydroxylation and suppresses the Warburg effect.
Zhang CS; Liu Q; Li M; Lin SY; Peng Y; Wu D; Li TY; Fu Q; Jia W; Wang X; Ma T; Zong Y; Cui J; Pu C; Lian G; Guo H; Ye Z; Lin SC
Cell Res; 2015 Sep; 25(9):1025-42. PubMed ID: 26215701
[TBL] [Abstract][Full Text] [Related]
5. The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIM(EL).
Guo Y; Schoell MC; Freeman RS
Oncogene; 2009 Apr; 28(16):1864-74. PubMed ID: 19305426
[TBL] [Abstract][Full Text] [Related]
6. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
7. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
[TBL] [Abstract][Full Text] [Related]
8. Three novel VHL germline mutations in Korean patients with von Hippel-Lindau disease and pheochromocytomas.
Kang HC; Kim IJ; Park JH; Shin Y; Jang SG; Ahn SA; Park HW; Lim SK; Oh SK; Kim DJ; Lee KW; Choi YS; Park YJ; Lee MR; Kim DW; Park JG
Oncol Rep; 2005 Oct; 14(4):879-83. PubMed ID: 16142346
[TBL] [Abstract][Full Text] [Related]
9. The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma.
Peng S; Zhang J; Tan X; Huang Y; Xu J; Silk N; Zhang D; Liu Q; Jiang J
Front Endocrinol (Lausanne); 2020; 11():586857. PubMed ID: 33329393
[TBL] [Abstract][Full Text] [Related]
10. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
11. EGLN3 prolyl hydroxylase regulates skeletal muscle differentiation and myogenin protein stability.
Fu J; Menzies K; Freeman RS; Taubman MB
J Biol Chem; 2007 Apr; 282(17):12410-8. PubMed ID: 17344222
[TBL] [Abstract][Full Text] [Related]
12. Proline Hydroxylation Primes Protein Kinases for Autophosphorylation and Activation.
Lee SB; Ko A; Oh YT; Shi P; D'Angelo F; Frangaj B; Koller A; Chen EI; Cardozo T; Iavarone A; Lasorella A
Mol Cell; 2020 Aug; 79(3):376-389.e8. PubMed ID: 32640193
[TBL] [Abstract][Full Text] [Related]
13. Hydroxylation-Dependent Interaction of Substrates to the Von Hippel-Lindau Tumor Suppressor Protein (VHL).
Heir P; Ohh M
Methods Mol Biol; 2016; 1458():87-94. PubMed ID: 27581016
[TBL] [Abstract][Full Text] [Related]
14. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
15. Seven Novel Genes Related to Cell Proliferation and Migration of VHL-Mutated Pheochromocytoma.
Gao S; Liu L; Li Z; Pang Y; Shi J; Zhu F
Front Endocrinol (Lausanne); 2021; 12():598656. PubMed ID: 33828526
[TBL] [Abstract][Full Text] [Related]
16. Impaired oxygen-sensitive regulation of mitochondrial biogenesis within the von Hippel-Lindau syndrome.
Li S; Li W; Yuan J; Bullova P; Wu J; Zhang X; Liu Y; Plescher M; Rodriguez J; Bedoya-Reina OC; Jannig PR; Valente-Silva P; Yu M; Henriksson MA; Zubarev RA; Smed-Sörensen A; Suzuki CK; Ruas JL; Holmberg J; Larsson C; Christofer Juhlin C; von Kriegsheim A; Cao Y; Schlisio S
Nat Metab; 2022 Jun; 4(6):739-758. PubMed ID: 35760869
[TBL] [Abstract][Full Text] [Related]
17. Case report: a synonymous VHL mutation (c.414A > G, p.Pro138Pro) causes pathogenic familial hemangioblastoma through dysregulated splicing.
Liu F; Calhoun B; Alam MS; Sun M; Wang X; Zhang C; Haldar K; Lu X
BMC Med Genet; 2020 Feb; 21(1):42. PubMed ID: 32106822
[TBL] [Abstract][Full Text] [Related]
18. The HIF and other quandaries in VHL disease.
Tarade D; Ohh M
Oncogene; 2018 Jan; 37(2):139-147. PubMed ID: 28925400
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
[TBL] [Abstract][Full Text] [Related]
20. Oxygen-dependent Regulation of Erythropoietin Receptor Turnover and Signaling.
Heir P; Srikumar T; Bikopoulos G; Bunda S; Poon BP; Lee JE; Raught B; Ohh M
J Biol Chem; 2016 Apr; 291(14):7357-72. PubMed ID: 26846855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
